"I am pleased to tell you that Guangdong has begun an animal vaccine protection trial of mRNA vaccines today." On the 19th, at the Guangdong Science and Technology Center's theme exhibition "Guangdong Science and Technology Support to Win the Epidemic Prevention and Control Strike", Guangdong Science and Technology Director Wang Ruijun revealed in an interview with reporters.
Guangdong's science and technology war was "epidemic" and moved quickly. Emergency operation on January 19, and project deployment on January 23. In response to the COVID-19 epidemic, the Guangdong Provincial Department of Science and Technology established an expert group headed by Academician Zhong Nanshan to organize the implementation of three batches of emergency scientific research projects, focusing on clinical treatment and drugs, vaccine research and development, detection technology and products, viral etiology and epidemic Five main directions of attack, such as pathology and animal model construction.
In terms of vaccine research and development, Guangdong has been advancing the development of adenovirus vector vaccines, recombinant protein vaccines, and mRNA vaccines in parallel, and has made progress in stages.
Compared with traditional inactivated vaccines and live attenuated vaccines, the development of mRNA vaccines is more convenient and efficient. During the development process, inactivated vaccines and live attenuated vaccines need to amplify live viruses, and the challenges of expanding scale facilities and safety prevention and control are greater. The development of mRNA vaccines does not require the amplification of viruses. The key step is to synthesize an mRNA that can be translated into specific proteins in vitro. This technology is now very mature.
Wang Ruijun revealed that in addition to mRNA vaccines, adenoviral vector vaccines will also carry out animal experiments on these two days. He said: "Our biggest feature is the organization of superior scientific and technological forces, the implementation of large alliances, large team operations, production-university-research integration, and the rapid application of scientific and technological achievements in clinical practice. At the same time, we have established clinical treatment as the core and insisted on combining scientific research with clinical Application of scientific and technological achievements to the front line of the epidemic. "
0 Comments